Events
Search Results
WSGR Events
5.14.26
Biotech's New Playbook: Spinouts and Optionality
Biotechnology companies are increasingly using single-asset spinouts as a way to create value, though the approach can be complex. This afternoon forum will examine considerations to strategically design and execute a successful spinout. Attendees will gain insight into the legal foundations of these transactions, including tax considerations, patent strategy, IP allocation, and structural design. The program will also explore the broader business drivers behind spinout decisions—such as capital formation, strategic focus, partnership alignment, governance, and long-term value creation.
Affiliated Programs
2.24.26
Biocom Global Partnering and Investor Conference
Wilson Sonsini is a proud supporter of Biocom's Global Partnering and Investor Conference. This exclusive forum forum brings together over 500 investors and senior executives, including CEOs and heads of business development, biotech, and research and development from leading pharmaceutical, biotech, and research organizations from over 20 countries. Wilson Sonsini Corporate partner Jason Skolnik will be moderating a VC Insights discussion on February 26, from 3:30-4:30 PM featuring:
Affiliated Programs
6.11.25
San Diego Innovation Council 2025 Innovation Showcase
Wilson Sonsini is pleased to support the 2025 Innovation Showcase, hosted by the San Diego Innovation Council on June 11. This day-long event highlights emerging technologies from leading academic institutions across San Diego and Southern California, featuring presentations and networking opportunities in sectors including software, engineering, clean tech, agriculture, and life sciences. The showcase brings together research-driven innovations, success stories, and early-stage ventures seeking to move from lab to market.
WSGR Events
6.15.23
Wilson Sonsini’s 30th Annual Medical Device Digital Health Conference
Wilson Sonsini’s 30th Annual Medical Device Digital Health Conference will address topics of critical importance to medical device and digital health companies today, including key healthcare regulatory considerations, the relationship between intellectual property and valuation, a look back at 2022’s fundraising and deals, and how 2023 is shaping up along with partnering strategies in the current market.
Speaking Engagements
6.28.22
What is Your Company Worth: The Art of Company Valuation
Wilson Sonsini is pleased to support LaunchBio’s Founders Circle gathering, What is Your Company Worth: The Art of Company Valuation. You’ve started your life science company and are now working on a proof of concept and a plan for commercialization. Your innovation may drive the development of new drugs, diagnostics, or technology platforms to help patients. As you form partnerships to take your enterprise to the next level, the question will arise: What is your company worth?
Affiliated Programs
2.25.20
LaunchBio: Larger Than Life Science, Critical Cash-How to Raise Non-Dilutive Funding
Wilson Sonsini Goodrich & Rosati is pleased to sponsor LaunchBio’s Larger Than Life Science, Critical Cash-How to Raise Non-Dilutive Funding. Biotech and life science startups often rely on government industry grants, including the Small Business Innovation Research (SBIR) and Technology Transfer (STTR) programs, which are designed to enable the commercialization of cutting-edge technologies. Other sources of non-dilutive funding include foundations, industry partnerships, and venture debt. While these can be important sources of cash, non-dilutive funds are not “free” and can have some unintended consequences and costs. A variety of perspectives—entrepreneur, investor, entrepreneurial support organization and legal expert—will be presented on how to secure and deploy this type of “critical cash.”